## **AMENDMENTS TO THE CLAIMS:**

This listing of the claims below will replace all prior versions and listing of claims in this application.

## Claim 1. (Original)

An imidazotriazinone compound represented by the following formula (IA) or (IB):

wherein

A is N or CR<sup>4</sup>;

B is N or CH;

R<sup>1</sup> is substituted or unsubstituted cycloalkyl group or tert-butyl group;

 $R^2$  is a hydrogen atom or  $C_1$ - $C_6$  alkyl group;

 $R^3$  is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted  $C_1$ - $C_6$  alkyl group; substituted or unsubstituted  $C_2$ - $C_6$  alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: -  $NR^5R^6$ , - $C(O)R^7$ , - $SO_2R^7$ , - $OR^8$ , - $NR^8COR^7$ , - $NR^8SO_2R^7$ ;

 $R^4$  is a hydrogen atom or  $C_1$ - $C_3$  alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R<sup>5</sup> and R<sup>6</sup> are, same or different from each other, a hydrogen atom; substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group; substituted or unsubstituted acyl group; or substituted or unsubstituted heterocycloalkyl group;

 $R^7$  is a hydrogen atom; substituted or unsubstituted  $C_1$ - $C_6$  alkyl group; substituted or unsubstituted heterocycloalkyl group; OH; -OR $^8$  or -NR $^5$ R $^6$ ;

 $R^8$  is a hydrogen atom, substituted or unsubstituted  $C_1$ - $C_6$  alkyl group; or substituted or unsubstituted heterocycloalkyl group; or pharmaceutically acceptable salts or solvates thereof. Claim 2. (Original) The compound represented by the formula (IA) according to claim 1.

Claim 3. (Original) The compound represented by the formula (IB) according to claim 1.

- Claim 4. (Original) The compound according to claim 1, 2 or 3, in which  $R^1$  is substituted or unsubstituted  $C_3$ - $C_8$  cycloalkyl group.
- Claim 5. (Currently Amended) The compound according to claim 4, in which R<sup>1</sup> is selected from the group consisting of cyclopentyl, cyclohexyl and or cycloheptyl.
- Claim 6. (Currently Amended) The compound according to any one of claims 1 to 5 claim 1, in which A is  $CR^4$  wherein  $R^4$  is methoxy or ethoxy group.
- Claim 7. (Currently Amended) The compound according to any one of claims 1 to 6 claim 1, in which B is CH.
- Claim 8. (Currently Amended) The compound according to any one of claims 1 to 7 claim 1, in which  $R^2$  is methyl group.
- Claim 9. (Currently Amended) The compound according to any one of claims 1 to 8 claim 1, in which  $R^3$  is a haydrogen hydrogen atom; a halogen atom; saturated or unsaturated heterocycloalkyl group; an group selected from the -NR<sup>5</sup>R<sup>6</sup>, -C(O)R<sup>7</sup>, or and -SO<sub>2</sub>R<sup>7</sup> group, wherein  $R^7$  is OH, -OR<sup>8</sup>, -NR<sup>5</sup>R<sup>6</sup> or a and substituted or unsubstituted heterocycloalkyl group.
- Claim 10. (**Currently Amended**) A pharmaceutical composition <u>comprising containing</u> a compound according to <u>any one of claims 1 to 9 claim 1</u>, or pharmaceutically acceptable salts or solvates thereof as active ingredient.
- Claim 11. (**Currently Amended**) A PDE 7 inhibitor <u>comprising eontaining</u> a compound according to <u>any one of claims 1 to 9 claim 1</u>, or pharmaceutically acceptable salts or solvates thereof as active ingredient.